Navigation Links
BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2010 Financial Results
Date:3/11/2011

ore information about The Company may be found on its website at www.biospecifics.com.

Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding the Company's strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, its expected revenue growth, and any other statements containing the words "believes," "expects," "anticipates," "plans," "estimates" and similar expressions, are forward-looking statements. There are a number of important factors that could cause its actual results to differ materially from those indicated by such forward-looking statements, including the statements made by the Company and by its partner Auxilium regarding the availability of a XIAFLEX specific CPT code; the ability of Pfizer to achieve its objectives for XIAPEX in Europe; the success of the Phase III trials for XIAFLEX for the treatment of Peyronie's disease, which will determine the amount of milestone, royalty and sublicense income payments the Company may receive; the outcome of the dispute with Auxilium; the Company's ability to restart the Chien-803 trial; the Company's ability to initiate and complete clinical trials in additional indications; and other risk factors identified in the Company's Form 10-K for the year ended December 31, 2009 and its reports on Form 8-K filed with the U.S. Securities and Exchange Commission. All forward-looking statements included in this press release are made as of the date hereof, and the Company assumes no obligation to update these forward-looking statements. BioSpecifics Technologies Corp.Consolidated Statements of OperationsThree months endedTwelve months endedDecember 31December 312010200920102009Revenues:(Unaudited)(Audited)
'/>"/>

SOURCE BioSpecifics Technologies Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. BioSpecifics Technologies Corp. Reports Second Quarter 2008 Financial Results
2. BioSpecifics Technologies Corp. Buys Down Royalties for Peyronies Disease
3. BioSpecifics Technologies Corp. Announces Appointment of Dr. Matthew Geller to Board of Directors
4. BioSpecifics Technologies Corp. to Present at Piper Jaffray 20th Annual Health Care Conference
5. BioSpecifics Technologies Corp. Announces Listing on NASDAQ Global Market
6. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results
7. BioSpecifics Technologies Corp. Announces FDA Acceptance of Biologics License Application With Priority Review for XIAFLEX(TM) for the Treatment of Dupuytrens Disease
8. BioSpecifics Technologies Corp. Reports First Quarter 2009 Financial Results
9. BioSpecifics Technologies Corp. Added to Russell 3000 and Russell 2000 Indexes
10. BioSpecifics Technologies Corp. to Present at CapStone Investments Third Annual Small-Cap Investor Conference
11. BioSpecifics Technologies Corp. to Host Conference Call to Report Second Quarter 2009 Financial Results on August 12, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... San Diego, California (PRWEB) January 22, 2015 ... R Promotional Offer to their comprehensive portfolio of ... Offer allows customers to purchase a Centrifuge 5424/5424 R ... Pipette Bundle of either Eppendorf Research plus or Eppendorf ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Selexis SA, ... mammalian Research Cell Banks (RCBs) used for drug discovery ... Cell Banks will include Next-Generation Sequencing (NGS) ... architecture de-risks biologic manufacturing by ensuring the integrity of ...
(Date:1/22/2015)... 2015  Varian Medical Systems (NYSE: VAR ), world ... its commitment to sustainability with inclusion on a prestigious list ... ranked healthcare equipment company among the Corporate Knights Global 100 ... Forum at Davos, Switzerland . ...
(Date:12/24/2014)... Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... MDT ) has submitted a pre-market approval application ... the use of Medtronic,s SynchroMed ® II implantable ... use with United Therapeutics, Remodulin ® (treprostinil) Injection ...
Breaking Biology Technology:Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Varian Honored Among World's 100 Most Sustainable Corporations 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4
... on ... HeartMate II(R), PLEASANTON, Calif., Oct. 30 Thoratec,Corporation (Nasdaq: ... therapies to save, support and restore failing hearts,today said that ... revenues in the same period a year ago., Revenues ...
... (Nasdaq: ANDS ) announced today that it has ... virus (HCV) in Part B of a,two-part protocol designed ... ANA773 is the Company,s investigational oral TLR7 agonist,prodrug. In ... cohort will receive,800 mg of ANA773 every other day ...
... 30 In a joint press conference,Orange Romania ... cellular e-health service., "Health is the fundamental ... why,Orange and Medic4all are launching together the Medic4you ... Services Development,Manager for Orange Romania., Medic4you is ...
Cached Biology Technology:Thoratec Reports 44 Percent Increase in Third Quarter Revenues 2Thoratec Reports 44 Percent Increase in Third Quarter Revenues 3Thoratec Reports 44 Percent Increase in Third Quarter Revenues 4Thoratec Reports 44 Percent Increase in Third Quarter Revenues 5Thoratec Reports 44 Percent Increase in Third Quarter Revenues 6Thoratec Reports 44 Percent Increase in Third Quarter Revenues 7Thoratec Reports 44 Percent Increase in Third Quarter Revenues 8Thoratec Reports 44 Percent Increase in Third Quarter Revenues 9Thoratec Reports 44 Percent Increase in Third Quarter Revenues 10Thoratec Reports 44 Percent Increase in Third Quarter Revenues 11Thoratec Reports 44 Percent Increase in Third Quarter Revenues 12Thoratec Reports 44 Percent Increase in Third Quarter Revenues 13Thoratec Reports 44 Percent Increase in Third Quarter Revenues 14Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients 2Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients 3Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients 4Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients 5Orange and Medic4all Launched the World's First Cellular Tele-Health Service 2
(Date:12/22/2014)... 22, 2014 Research and Markets ( ... "The Global Watermarking and Fingerprinting Markets" ... http://photos.prnewswire.com/prnh/20130307/600769 This insight provides ... and fingerprinting markets. Watermarking aims to control and ...
(Date:12/19/2014)... 2014  23andMe, Inc., the leading personal genetics company, today announced ... genetic ancestry of individuals from across the United ... than four hundred years ago, the United States ... from different continents. This study illuminates how American history and ...
(Date:12/17/2014)... 2014  HITLAB SM announced today its completion of ... adherence to current U.S. Food and Drug Administration (FDA) ... device and smart phone application trials utilizing the highest ... "HITLAB is determined to improve global healthcare access, quality, ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2
... vegetable juice a daily habit could be a small ... daily vegetable recommendations, according to a new study being ... week at the American Dietetic Association annual conference 1 ... short of the daily recommended vegetable intake as put ...
... 23 Paradigm Tactical,Products Inc. (Pink Sheets: PDGT.PK), ... solutions to the military as well as to,the ... agreement,which will make the company the largest distributor ... and four additional detector models in,the United States. ...
... when raised on low calorie diets. But now researchers at ... that they can extend the life spans of roundworms even ... a chemical that blocks their sense of smell. Three ... reported they found that a class of anticonvulsant medications made ...
Cached Biology News:New study shows drinking your vegetables may be a solution to bridging the vegetable gap 2Paradigm Tactical Products to be Largest Distributor of Metal/Radiation Detection Wands in United States 2Paradigm Tactical Products to be Largest Distributor of Metal/Radiation Detection Wands in United States 3Deprived of a sense of smell, worms live longer 2
Immunogen: Synthetic peptide (KLH conjugated): L(506) S K S S S Q I R M S G L P A D N L A T(525) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Attachments: Clip bar for tubes 10 to 19 mm in diameter Overall Dimension Height IC: 6 (15.2) Overall Dimension Length IC: 18.5 (46.9) Overall Dimension Width IC: 4 (10.2)...
BD FastImmune EDTA Solution. Applications: Flow Cytometry Storage Temperature: Refrigerate(2 to 8C)...
... ,5-Bromo-4-chloro-3-indoxyl-beta-D-galactopyranoside C 14 H 15 ... ,M.W.= 408.63 ,Assay: Greater than ... DMF) ,Biological Activity: Blue color with ... Agrees with theoretical values ,Thin Layer ...
Biology Products: